Attitudes towards psychoactive drugs for the treatment of PTSD are changing, and for good reason – it’s hard to disagree with the evidence of the therapeutic benefits of psychedelic medicines for the treatment of mental illness. Compelling studies are being conducted around the world, several of them here at Monash. And it won’t be long until you see the results of these studies for yourself – experts suggest health care providers could begin prescribing psychedelic drugs for PTSD patients as soon as 2023.

In this episode of “What Happens Next?”, Dr Susan Carland talks to Dr Paul Liknaitzky, the principal investigator on a number of Australia’s first clinical psychedelic trials. She’s also joined by Dr Meaghan O’Donnell, head of research at Phoenix Australia and professor in the Department of Psychiatry at the University of Melbourne.

Learn how psychedelic drugs, in concert with more traditional therapies, can help trauma survivors shift their perceptions, and about some of the upcoming research that will revolutionise psychiatry and change the lives of millions of people suffering from mental illness.

To be added to Monash University’s notification list for psychedelic drug trial recruitment, email psychedelic@monash.edu.

See omnystudio.com/listener for privacy information.